ArticlePhysiology & behavior2015
Fluoxetine prevents the development of depressive-like behavior in a mouse model of cancer related fatigue.
Article in Physiology & behavior, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 2 syntheses or guidelines pooled it, 47 citations in OpenAlex.
- Bibliometric and visualization analyses of cancer-related fatigue research published worldwide from 2001 to 2023.Frontiers in oncology · 2024Pooled it
- Effects of Cognitive Training and Social Support on Cancer-Related Fatigue and Quality of Life in Colorectal Cancer Survivors: A Systematic Review and Meta-Analysis.Integrative cancer therapiesPooled it
- Anti-tumor effects and immuno-inflammatory-metabolic mechanisms of Buzhong Yiqi Granules in improving cancer-related fatigue in lung cancer.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2026Article
- Comprehensive review of mouse models for studying cancer-related fatigue: Methods, findings and future directions (Review).Experimental and therapeutic medicine · 2025Review
- The central role of microglia in major depressive disorder and its potential as a therapeutic target.Frontiers in behavioral neuroscience · 2025Review
- Article
- Effects of acteoside fromFrontiers in pharmacology · 2024Article
- The Anti-Neuroinflammatory Effect of Fuzi and Ganjiang Extraction on LPS-Induced BV2 Microglia and Its Intervention Function on Depression-Like Behavior of Cancer-Related Fatigue Model Mice.Frontiers in pharmacology · 2021Article
- Toll-like receptor 4 mediates the development of fatigue in the murine Lewis Lung Carcinoma model independently of activation of macrophages and microglia.Psychoneuroendocrinology · 2020Article
- Inflammation-Induced Tryptophan Breakdown is Related With Anemia, Fatigue, and Depression in Cancer.Frontiers in immunology · 2020Review
- Inflammation in cancer and depression: a starring role for the kynurenine pathway.Psychopharmacology · 2019Review
- Central regulation of breast cancer growth and metastasis.Journal of cancer metastasis and treatment · 2019Article
- Comparing passive measures of fatigue-like behavior in mice.Scientific reports · 2018Article
- Tumor-Associated Fatigue in Cancer Patients Develops Independently of IL1 Signaling.Cancer research · 2018Article
- Article
- Rescue of IL-1β-induced reduction of human neurogenesis by omega-3 fatty acids and antidepressants.Brain, behavior, and immunity · 2017Article
- Microglia Loss Contributes to the Development of Major Depression Induced by Different Types of Chronic Stresses.Neurochemical research · 2017Article
- Synaptic Loss and the Pathophysiology of PTSD: Implications for Ketamine as a Prototype Novel Therapeutic.Current psychiatry reports · 2017Review
- Neuroinflammatory and cognitive consequences of combined radiation and immunotherapy in a novel preclinical model.Oncotarget · 2017Article
- Role of the Kynurenine Metabolism Pathway in Inflammation-Induced Depression: Preclinical Approaches.Current topics in behavioral neurosciences · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 1 institution in 1 country.
Funding
Abstract
Cancer patients frequently suffer from fatigue, a complex syndrome associated with tiredness and depressed mood. Cancer-related fatigue (CRF) can be present at the time of diagnosis, escalates during treatment, and can persist for years after treatment. CRF negatively influences quality of life, limits functional independence, and is associated with decreased survival in patients with incurable disease. We have previously shown that increased pro-inflammatory cytokine expression in the brain contributes to depressive- and fatigue-like behaviors in a mouse model of CRF. Inflammatory cytokines increase the activity of indoleamine 2,3-dioxygenase (IDO) and kynurenine 3-monooxygenase (KMO), which competitively reduce serotonin synthesis. Reduced serotonin availability in the brain and increased production of alternative neuroactive metabolites of tryptophan are thought to contribute to the development of depression and fatigue. The purpose of this study was to determine the effects of fluoxetine, a selective serotonin reuptake inhibitor (SSRI), on brain cytokines and behavioral measures of fatigue and depression in tumor-bearing mice. Here we show that tumor growth increased brain expression of pro-inflammatory cytokines and KMO. Treatment with fluoxetine had no effect on tumor growth, muscle wasting, fatigue behavior, or cytokine expression in the brain. Fluoxetine, however, reduced depressive-like behaviors in tumor bearing mice. In conclusion, our data confirm that increased brain expression of pro-inflammatory cytokines is associated with tumor-induced fatigue- and depressive-like behaviors. However, it is possible to separate the effects of tumor growth on mood and fatigue-like behaviors using SSRIs such as fluoxetine.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.